PASI 75 [18] (multiple letters)

Journal of the American Academy of Dermatology

Volumn 52, Issue 1, 2005, Pages 183-184

  Rapaport, Marvin J ^a,b   Krueger, Gerald G ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b C AND EN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRETIN; METHOTREXATE; PSORALEN; BIOLOGICAL PRODUCT;

COST OF ILLNESS; DISEASE SEVERITY; DRUG EFFECT; HUMAN; LETTER; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; RATING SCALE; SCORING SYSTEM; SYSTEMIC THERAPY; ULTRAVIOLET A RADIATION; CLINICAL TRIAL; HOSPITALIZATION; NOTE; PSORIASIS;

BIOLOGICAL PRODUCTS; CLINICAL TRIALS; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 11144283654     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.07.018     Document Type: Letter

References (6)

1. B. Goffe J.C. Cather Ethanercept: an overview J Am Acad Dermatol 49 2003 105 111
2. A. Gottlieb Infliximab for psoriasis J Am Acad Dermatol 49 2003 S112 S117
3. G. Krueger K. Callis Development and use of alefacept to treat psoriasis J Am Acad Dermatol 49 2003 S87 S97
4. C. Leonardi Falizumab: an overview J Am Acad Dermatol 49 2003 S98 S104
5. M. Lebwohl The use of biologics for the treatment of psoriasis [audiotape] Dialogues in Dermatology 2003
6. A. Gottlieb U. Chaudhari D. Baker M. Perate L. Dooley The National Psoriasis Foundation Psoriasis Score (NPF-PS) System versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison J Drugs Dermatol 3 2003 260 266